Tesamorelin Therapy (Egrifta SV/Egrifta WR)

Tesamorelin is a growth hormone–releasing hormone (GHRH) analogue. It works by stimulating the pituitary gland to increase endogenous growth hormone secretion, which in turn raises insulin-like growth factor-1 (IGF-1) levels.

Key point upfront:

Tesamorelin is not a wellness supplement. It is a prescription drug with defined FDA labeling, contraindications, and monitoring requirements.

Tesamorelin, marketed as Egrifta SV and the newer formulation Egrifta WR, is FDA-approved for:

• Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy

This indication is specific and narrow. The clinical trials supporting approval were conducted in people living with HIV who developed visceral adipose tissue accumulation related to antiretroviral therapy.

FDA labeling and payer policy summaries also state clearly:

• Tesamorelin is not indicated for weight-loss management
• Overall body weight is generally described as weight-neutral

If you see Tesamorelin promoted for the following, that should raise questions:

• General weight loss
• “Belly fat reduction” in non-HIV patients
• Anti-aging or longevity therapy
• Body recomposition for the general population

These uses are not aligned with FDA-approved labeling and often overstate what the evidence supports. A responsible clinic does not blur this line.

Clinical trials in people living with HIV demonstrate that Tesamorelin can:

• Reduce visceral adipose tissue in the approved population
• Increase growth hormone and IGF-1 levels

Two realities remain important:

• The approved population is specific (HIV-associated lipodystrophy)
• Tesamorelin carries meaningful safety considerations that require monitoring

This is why Tesamorelin is not a casual, cosmetic, or lifestyle decision.

Tesamorelin is not low risk, and FDA labeling includes clear warnings.

Do not use Tesamorelin if you have:

• Active malignancy
  (Any prior malignancy should be inactive and treatment complete before consideration)
• Disruption of the hypothalamic-pituitary axis
  (Including pituitary tumors, pituitary surgery, head irradiation, head trauma, or hypopituitarism)
• Known hypersensitivity to Tesamorelin or its excipients

Key risks that must be discussed:

• Glucose intolerance and diabetes risk
  FDA labeling warns Tesamorelin may result in glucose intolerance and recommends careful evaluation and monitoring.
• Fluid retention
  May cause edema, joint pain, carpal tunnel symptoms, or musculoskeletal discomfort.
• Elevated IGF-1 levels
  This is why malignancy screening and ongoing monitoring matter.

Egrifta WR prescribing information reflects ongoing labeling updates, with initial U.S. approval of Tesamorelin dating back to 2010.

Egrifta WR is a newer formulation of Tesamorelin.

Important points:

• Egrifta WR and Egrifta SV are not interchangeable
• They differ in strength, preparation, and administration instructions
• Substitution without proper medical guidance is not appropriate

This is another reason Tesamorelin requires prescription-level oversight.

Tesamorelin is never assumed to be appropriate.

An online consultation typically includes:

• Clarifying whether the FDA-approved indication applies
• Review of medical history and exclusions
• Assessment of glucose risk factors and monitoring needs
• Discussion of realistic outcomes and limitations
• A clear decision to proceed — or not

If Tesamorelin does not fit, we say so. There is no pressure.

Is Tesamorelin FDA-approved for weight loss?
No. Tesamorelin is approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight-loss management.

Does Tesamorelin increase growth hormone?
Yes. Tesamorelin is a GHRH analogue that increases endogenous growth hormone secretion and raises IGF-1 levels.

Who should not take Tesamorelin?
Individuals with active malignancy, disruption of the hypothalamic-pituitary axis, or hypersensitivity to Tesamorelin or its excipients.

Can Tesamorelin affect blood sugar?
Yes. FDA labeling warns about glucose intolerance and recommends careful evaluation and monitoring.

If you are considering Tesamorelin, the most important question is simple:
Does the FDA-approved indication and your medical profile actually support it?

Vitalé offers secure online consultations nationwide, focused on:

• Determining whether Tesamorelin is appropriate
• Reviewing risks, contraindications, and monitoring needs
• Avoiding off-label hype and unsafe decisions

Book an online consultation to discuss Tesamorelin in a medically grounded, transparent way.